Takeda releases positive Phase II data on mezagitamab in primary ITP

25 June 2025

Japan’s largest drugmaker Takeda (TYO: 4502) presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or chronic primary immune thrombocytopenia (ITP).

The data – presented at the International Society on Thrombosis and Hemostasis (ISTH) 2025 Congress in Washington DC showed that patients (n=28) treated with mezagitamab achieved rapid and durable platelet response and improved health-related quality of life scores through week 16 compared to placebo.

Additionally, rapid platelet response with mezagitamab could be seen two days after the first dose and the duration of platelet response increased in all mezagitamab groups in a dose-dependent manner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK